nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.327	1	CbGbCtD
Citalopram—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00432	0.0723	CbGeAlD
Citalopram—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00418	0.00722	CcSEcCtD
Citalopram—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00418	0.00722	CcSEcCtD
Citalopram—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00712	CcSEcCtD
Citalopram—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00693	CcSEcCtD
Citalopram—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00693	CcSEcCtD
Citalopram—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00666	CcSEcCtD
Citalopram—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00666	CcSEcCtD
Citalopram—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00658	CcSEcCtD
Citalopram—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00658	CcSEcCtD
Citalopram—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0065	CcSEcCtD
Citalopram—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00642	CcSEcCtD
Citalopram—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00642	CcSEcCtD
Citalopram—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00642	CcSEcCtD
Citalopram—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00368	0.00634	CcSEcCtD
Citalopram—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00363	0.00627	CcSEcCtD
Citalopram—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00619	CcSEcCtD
Citalopram—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00619	CcSEcCtD
Citalopram—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00612	CcSEcCtD
Citalopram—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00605	CcSEcCtD
Citalopram—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00349	0.0583	CbGeAlD
Citalopram—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00599	CcSEcCtD
Citalopram—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00599	CcSEcCtD
Citalopram—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00336	0.0058	CcSEcCtD
Citalopram—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00567	CcSEcCtD
Citalopram—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00562	CcSEcCtD
Citalopram—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00324	0.0541	CbGeAlD
Citalopram—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00556	CcSEcCtD
Citalopram—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00556	CcSEcCtD
Citalopram—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00545	CcSEcCtD
Citalopram—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00313	0.0054	CcSEcCtD
Citalopram—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00534	CcSEcCtD
Citalopram—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00529	CcSEcCtD
Citalopram—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00529	CcSEcCtD
Citalopram—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00304	0.00524	CcSEcCtD
Citalopram—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00519	CcSEcCtD
Citalopram—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00298	0.00515	CcSEcCtD
Citalopram—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00298	0.00515	CcSEcCtD
Citalopram—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00298	0.00515	CcSEcCtD
Citalopram—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00297	0.0496	CbGeAlD
Citalopram—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0051	CcSEcCtD
Citalopram—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0051	CcSEcCtD
Citalopram—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00505	CcSEcCtD
Citalopram—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00505	CcSEcCtD
Citalopram—Mania—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00501	CcSEcCtD
Citalopram—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00488	CcSEcCtD
Citalopram—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00484	CcSEcCtD
Citalopram—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00484	CcSEcCtD
Citalopram—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00472	CcSEcCtD
Citalopram—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00267	0.0046	CcSEcCtD
Citalopram—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00453	CcSEcCtD
Citalopram—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00453	CcSEcCtD
Citalopram—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00261	0.0045	CcSEcCtD
Citalopram—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00443	CcSEcCtD
Citalopram—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00439	CcSEcCtD
Citalopram—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00423	CcSEcCtD
Citalopram—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.00243	0.0406	CbGeAlD
Citalopram—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00417	CcSEcCtD
Citalopram—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00415	CcSEcCtD
Citalopram—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00412	CcSEcCtD
Citalopram—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00406	CcSEcCtD
Citalopram—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00403	CcSEcCtD
Citalopram—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00401	CcSEcCtD
Citalopram—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00401	CcSEcCtD
Citalopram—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00398	CcSEcCtD
Citalopram—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00395	CcSEcCtD
Citalopram—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00393	CcSEcCtD
Citalopram—Gout—Riluzole—amyotrophic lateral sclerosis	0.00226	0.0039	CcSEcCtD
Citalopram—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00388	CcSEcCtD
Citalopram—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00385	CcSEcCtD
Citalopram—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00385	CcSEcCtD
Citalopram—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00385	CcSEcCtD
Citalopram—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00383	CcSEcCtD
Citalopram—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00373	CcSEcCtD
Citalopram—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00371	CcSEcCtD
Citalopram—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00369	CcSEcCtD
Citalopram—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00364	CcSEcCtD
Citalopram—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00364	CcSEcCtD
Citalopram—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00364	CcSEcCtD
Citalopram—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00364	CcSEcCtD
Citalopram—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0036	CcSEcCtD
Citalopram—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0036	CcSEcCtD
Citalopram—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00356	CcSEcCtD
Citalopram—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00352	CcSEcCtD
Citalopram—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00352	CcSEcCtD
Citalopram—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00348	CcSEcCtD
Citalopram—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.002	0.00346	CcSEcCtD
Citalopram—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00342	CcSEcCtD
Citalopram—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00342	CcSEcCtD
Citalopram—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00335	CcSEcCtD
Citalopram—Coma—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00333	CcSEcCtD
Citalopram—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00329	CcSEcCtD
Citalopram—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00329	CcSEcCtD
Citalopram—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00186	0.031	CbGeAlD
Citalopram—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00319	CcSEcCtD
Citalopram—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00316	CcSEcCtD
Citalopram—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00316	CcSEcCtD
Citalopram—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00313	CcSEcCtD
Citalopram—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0031	CcSEcCtD
Citalopram—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0031	CcSEcCtD
Citalopram—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00179	0.03	CbGeAlD
Citalopram—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00307	CcSEcCtD
Citalopram—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00304	CcSEcCtD
Citalopram—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00304	CcSEcCtD
Citalopram—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00296	CcSEcCtD
Citalopram—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00296	CcSEcCtD
Citalopram—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00294	CcSEcCtD
Citalopram—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.0017	0.0284	CbGeAlD
Citalopram—Injury—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00288	CcSEcCtD
Citalopram—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00285	CcSEcCtD
Citalopram—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00281	CcSEcCtD
Citalopram—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00281	CcSEcCtD
Citalopram—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00279	CcSEcCtD
Citalopram—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00278	CcSEcCtD
Citalopram—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00274	CcSEcCtD
Citalopram—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00272	CcSEcCtD
Citalopram—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00271	CcSEcCtD
Citalopram—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00265	CcSEcCtD
Citalopram—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00264	CcSEcCtD
Citalopram—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00264	CcSEcCtD
Citalopram—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00264	CcSEcCtD
Citalopram—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00262	CcSEcCtD
Citalopram—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0026	CcSEcCtD
Citalopram—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0026	CcSEcCtD
Citalopram—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.0015	0.025	CbGeAlD
Citalopram—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00258	CcSEcCtD
Citalopram—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00255	CcSEcCtD
Citalopram—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00251	CcSEcCtD
Citalopram—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00251	CcSEcCtD
Citalopram—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00145	0.0025	CcSEcCtD
Citalopram—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00249	CcSEcCtD
Citalopram—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00143	0.0239	CbGeAlD
Citalopram—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00246	CcSEcCtD
Citalopram—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00244	CcSEcCtD
Citalopram—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00241	CcSEcCtD
Citalopram—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00241	CcSEcCtD
Citalopram—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00139	0.0233	CbGeAlD
Citalopram—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00239	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00238	CcSEcCtD
Citalopram—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00234	CcSEcCtD
Citalopram—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00233	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00233	CcSEcCtD
Citalopram—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00133	0.0023	CcSEcCtD
Citalopram—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00229	CcSEcCtD
Citalopram—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00229	CcSEcCtD
Citalopram—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00229	CcSEcCtD
Citalopram—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00224	CcSEcCtD
Citalopram—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00223	CcSEcCtD
Citalopram—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0022	CcSEcCtD
Citalopram—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00219	CcSEcCtD
Citalopram—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00217	CcSEcCtD
Citalopram—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.00125	0.0209	CbGeAlD
Citalopram—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00214	CcSEcCtD
Citalopram—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00211	CcSEcCtD
Citalopram—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0021	CcSEcCtD
Citalopram—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00209	CcSEcCtD
Citalopram—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00208	CcSEcCtD
Citalopram—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00207	CcSEcCtD
Citalopram—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00205	CcSEcCtD
Citalopram—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00204	CcSEcCtD
Citalopram—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00204	CcSEcCtD
Citalopram—Depression—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00203	CcSEcCtD
Citalopram—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00201	CcSEcCtD
Citalopram—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00116	0.002	CcSEcCtD
Citalopram—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00116	0.002	CcSEcCtD
Citalopram—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00115	0.0193	CbGeAlD
Citalopram—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00199	CcSEcCtD
Citalopram—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00199	CcSEcCtD
Citalopram—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00198	CcSEcCtD
Citalopram—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00195	CcSEcCtD
Citalopram—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00194	CcSEcCtD
Citalopram—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00193	CcSEcCtD
Citalopram—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00112	0.0186	CbGeAlD
Citalopram—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00192	CcSEcCtD
Citalopram—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00191	CcSEcCtD
Citalopram—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0019	CcSEcCtD
Citalopram—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00186	CcSEcCtD
Citalopram—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00184	CcSEcCtD
Citalopram—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00183	CcSEcCtD
Citalopram—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00183	CcSEcCtD
Citalopram—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00183	CcSEcCtD
Citalopram—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00106	0.0177	CbGeAlD
Citalopram—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00182	CcSEcCtD
Citalopram—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00182	CcSEcCtD
Citalopram—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00182	CcSEcCtD
Citalopram—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00181	CcSEcCtD
Citalopram—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0018	CcSEcCtD
Citalopram—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00104	0.0175	CbGeAlD
Citalopram—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0018	CcSEcCtD
Citalopram—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00179	CcSEcCtD
Citalopram—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.001	0.00173	CcSEcCtD
Citalopram—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000991	0.00171	CcSEcCtD
Citalopram—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000984	0.0017	CcSEcCtD
Citalopram—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.000972	0.0163	CbGeAlD
Citalopram—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000962	0.00166	CcSEcCtD
Citalopram—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000958	0.00165	CcSEcCtD
Citalopram—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000956	0.00165	CcSEcCtD
Citalopram—Chills—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00164	CcSEcCtD
Citalopram—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000947	0.00163	CcSEcCtD
Citalopram—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00094	0.0157	CbGeAlD
Citalopram—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000937	0.00162	CcSEcCtD
Citalopram—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.000936	0.0156	CbGeAlD
Citalopram—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000929	0.0016	CcSEcCtD
Citalopram—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000923	0.00159	CcSEcCtD
Citalopram—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.000915	0.0153	CbGeAlD
Citalopram—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000909	0.00157	CcSEcCtD
Citalopram—Tension—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00156	CcSEcCtD
Citalopram—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.000905	0.0151	CbGeAlD
Citalopram—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000904	0.00156	CcSEcCtD
Citalopram—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000896	0.00155	CcSEcCtD
Citalopram—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00154	CcSEcCtD
Citalopram—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.000891	0.0149	CbGeAlD
Citalopram—CHRM1—nervous system—amyotrophic lateral sclerosis	0.000887	0.0148	CbGeAlD
Citalopram—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000887	0.00153	CcSEcCtD
Citalopram—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000865	0.00149	CcSEcCtD
Citalopram—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.000858	0.0143	CbGeAlD
Citalopram—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00148	CcSEcCtD
Citalopram—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.000854	0.0143	CbGeAlD
Citalopram—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000853	0.00147	CcSEcCtD
Citalopram—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000848	0.00146	CcSEcCtD
Citalopram—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000843	0.00145	CcSEcCtD
Citalopram—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000832	0.00144	CcSEcCtD
Citalopram—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000829	0.00143	CcSEcCtD
Citalopram—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000828	0.00143	CcSEcCtD
Citalopram—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000826	0.00143	CcSEcCtD
Citalopram—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00082	0.0137	CbGeAlD
Citalopram—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000816	0.00141	CcSEcCtD
Citalopram—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000811	0.0014	CcSEcCtD
Citalopram—Cough—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00139	CcSEcCtD
Citalopram—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00138	CcSEcCtD
Citalopram—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000797	0.00137	CcSEcCtD
Citalopram—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00136	CcSEcCtD
Citalopram—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00136	CcSEcCtD
Citalopram—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00136	CcSEcCtD
Citalopram—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.000784	0.0131	CbGeAlD
Citalopram—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000783	0.00135	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00135	CcSEcCtD
Citalopram—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00134	CcSEcCtD
Citalopram—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000768	0.00133	CcSEcCtD
Citalopram—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00131	CcSEcCtD
Citalopram—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.000755	0.0126	CbGeAlD
Citalopram—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000753	0.0013	CcSEcCtD
Citalopram—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000753	0.0013	CcSEcCtD
Citalopram—Infection—Riluzole—amyotrophic lateral sclerosis	0.000748	0.00129	CcSEcCtD
Citalopram—SLC6A3—brain—amyotrophic lateral sclerosis	0.000743	0.0124	CbGeAlD
Citalopram—Shock—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00128	CcSEcCtD
Citalopram—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000739	0.00127	CcSEcCtD
Citalopram—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000738	0.00127	CcSEcCtD
Citalopram—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000735	0.00127	CcSEcCtD
Citalopram—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00126	CcSEcCtD
Citalopram—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.000729	0.0122	CbGeAlD
Citalopram—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000728	0.00126	CcSEcCtD
Citalopram—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	0.000722	0.0121	CbGeAlD
Citalopram—HTR2C—brain—amyotrophic lateral sclerosis	0.000718	0.012	CbGeAlD
Citalopram—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000718	0.00124	CcSEcCtD
Citalopram—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000704	0.00121	CcSEcCtD
Citalopram—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.000702	0.0117	CbGeAlD
Citalopram—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00118	CcSEcCtD
Citalopram—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.000686	0.0115	CbGeAlD
Citalopram—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000681	0.00118	CcSEcCtD
Citalopram—SLC6A4—brain—amyotrophic lateral sclerosis	0.000681	0.0114	CbGeAlD
Citalopram—CHRM1—brain—amyotrophic lateral sclerosis	0.000678	0.0113	CbGeAlD
Citalopram—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00117	CcSEcCtD
Citalopram—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00116	CcSEcCtD
Citalopram—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00067	0.00116	CcSEcCtD
Citalopram—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000663	0.00114	CcSEcCtD
Citalopram—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000655	0.00113	CcSEcCtD
Citalopram—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00065	0.00112	CcSEcCtD
Citalopram—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000649	0.00112	CcSEcCtD
Citalopram—Pain—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00111	CcSEcCtD
Citalopram—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00111	CcSEcCtD
Citalopram—CYP2E1—spinal cord—amyotrophic lateral sclerosis	0.000644	0.0108	CbGeAlD
Citalopram—ABCB1—embryo—amyotrophic lateral sclerosis	0.000643	0.0108	CbGeAlD
Citalopram—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000621	0.00107	CcSEcCtD
Citalopram—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000616	0.00106	CcSEcCtD
Citalopram—SLC6A2—brain—amyotrophic lateral sclerosis	0.000599	0.01	CbGeAlD
Citalopram—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00103	CcSEcCtD
Citalopram—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000595	0.00103	CcSEcCtD
Citalopram—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000595	0.00103	CcSEcCtD
Citalopram—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000578	0.00966	CbGeAlD
Citalopram—HRH1—nervous system—amyotrophic lateral sclerosis	0.000564	0.00944	CbGeAlD
Citalopram—ADRA1A—brain—amyotrophic lateral sclerosis	0.000557	0.00932	CbGeAlD
Citalopram—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000556	0.0093	CbGeAlD
Citalopram—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000555	0.000957	CcSEcCtD
Citalopram—HRH1—central nervous system—amyotrophic lateral sclerosis	0.000543	0.00909	CbGeAlD
Citalopram—CYP2E1—nervous system—amyotrophic lateral sclerosis	0.000542	0.00907	CbGeAlD
Citalopram—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00054	0.000932	CcSEcCtD
Citalopram—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000533	0.000919	CcSEcCtD
Citalopram—CYP2E1—central nervous system—amyotrophic lateral sclerosis	0.000522	0.00873	CbGeAlD
Citalopram—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000515	0.000889	CcSEcCtD
Citalopram—CYP2E1—cerebellum—amyotrophic lateral sclerosis	0.00051	0.00853	CbGeAlD
Citalopram—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000498	0.000859	CcSEcCtD
Citalopram—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000479	0.000826	CcSEcCtD
Citalopram—Rash—Riluzole—amyotrophic lateral sclerosis	0.000475	0.000819	CcSEcCtD
Citalopram—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000475	0.000819	CcSEcCtD
Citalopram—Headache—Riluzole—amyotrophic lateral sclerosis	0.000472	0.000814	CcSEcCtD
Citalopram—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000447	0.000772	CcSEcCtD
Citalopram—CYP2B6—brain—amyotrophic lateral sclerosis	0.000442	0.00739	CbGeAlD
Citalopram—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000436	0.0073	CbGeAlD
Citalopram—HRH1—brain—amyotrophic lateral sclerosis	0.000431	0.00721	CbGeAlD
Citalopram—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000429	0.00718	CbGeAlD
Citalopram—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.00042	0.00702	CbGeAlD
Citalopram—CYP2E1—brain—amyotrophic lateral sclerosis	0.000415	0.00693	CbGeAlD
Citalopram—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000413	0.00691	CbGeAlD
Citalopram—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000411	0.00687	CbGeAlD
Citalopram—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000404	0.00676	CbGeAlD
Citalopram—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000367	0.00613	CbGeAlD
Citalopram—CYP2D6—brain—amyotrophic lateral sclerosis	0.000328	0.00549	CbGeAlD
Citalopram—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000309	0.00516	CbGeAlD
Citalopram—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000297	0.00497	CbGeAlD
Citalopram—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000291	0.00486	CbGeAlD
Citalopram—ABCB1—brain—amyotrophic lateral sclerosis	0.000236	0.00395	CbGeAlD
Citalopram—CHRM1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	6.73e-05	0.00198	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	6.68e-05	0.00196	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	6.67e-05	0.00196	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	6.66e-05	0.00196	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	6.66e-05	0.00196	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	6.63e-05	0.00195	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	6.63e-05	0.00195	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	6.62e-05	0.00195	CbGpPWpGaD
Citalopram—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	6.62e-05	0.00194	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	6.59e-05	0.00194	CbGpPWpGaD
Citalopram—CYP2B6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.57e-05	0.00193	CbGpPWpGaD
Citalopram—CYP2B6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.48e-05	0.0019	CbGpPWpGaD
Citalopram—CYP2E1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.44e-05	0.00189	CbGpPWpGaD
Citalopram—CYP2E1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.35e-05	0.00187	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.09e-05	0.00179	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	6.01e-05	0.00177	CbGpPWpGaD
Citalopram—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.91e-05	0.00174	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	5.76e-05	0.00169	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.66e-05	0.00166	CbGpPWpGaD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	5.65e-05	0.00166	CbGpPWpGaD
Citalopram—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.39e-05	0.00158	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.32e-05	0.00156	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	5.09e-05	0.0015	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	5.04e-05	0.00148	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	5.04e-05	0.00148	CbGpPWpGaD
Citalopram—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.97e-05	0.00146	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.93e-05	0.00145	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.93e-05	0.00145	CbGpPWpGaD
Citalopram—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.9e-05	0.00144	CbGpPWpGaD
Citalopram—ADRA1A—AMPK Signaling—TP53—amyotrophic lateral sclerosis	4.83e-05	0.00142	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.68e-05	0.00138	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	4.61e-05	0.00135	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.57e-05	0.00134	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	4.54e-05	0.00133	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.51e-05	0.00133	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.51e-05	0.00132	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.47e-05	0.00131	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.4e-05	0.00129	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	4.35e-05	0.00128	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	4.29e-05	0.00126	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.28e-05	0.00126	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	4.26e-05	0.00125	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.2e-05	0.00123	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	4.1e-05	0.0012	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	4.03e-05	0.00118	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4e-05	0.00117	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.94e-05	0.00116	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.87e-05	0.00114	CbGpPWpGaD
Citalopram—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.87e-05	0.00114	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	3.87e-05	0.00114	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	3.86e-05	0.00113	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.82e-05	0.00112	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	3.81e-05	0.00112	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	3.81e-05	0.00112	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	3.81e-05	0.00112	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	3.8e-05	0.00112	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	3.8e-05	0.00112	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	3.74e-05	0.0011	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	3.72e-05	0.00109	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	3.72e-05	0.00109	CbGpPWpGaD
Citalopram—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	3.69e-05	0.00108	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.65e-05	0.00107	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	3.64e-05	0.00107	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—DAO—amyotrophic lateral sclerosis	3.57e-05	0.00105	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.55e-05	0.00104	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.5e-05	0.00103	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.5e-05	0.00103	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	3.49e-05	0.00102	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	3.48e-05	0.00102	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.46e-05	0.00102	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.45e-05	0.00101	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.4e-05	0.000999	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.4e-05	0.000999	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	3.4e-05	0.000998	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.29e-05	0.000968	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.29e-05	0.000968	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.24e-05	0.000951	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.2e-05	0.000941	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.16e-05	0.000928	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.12e-05	0.000916	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	3.04e-05	0.000894	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.99e-05	0.000878	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.98e-05	0.000875	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.97e-05	0.000873	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.97e-05	0.000871	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.97e-05	0.000871	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.95e-05	0.000866	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	2.95e-05	0.000866	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	2.94e-05	0.000863	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.94e-05	0.000863	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.93e-05	0.000861	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	2.89e-05	0.000849	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.8e-05	0.000822	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.79e-05	0.000818	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.78e-05	0.000816	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.77e-05	0.000813	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.76e-05	0.000811	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.75e-05	0.000809	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.71e-05	0.000797	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.7e-05	0.000794	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.7e-05	0.000793	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.69e-05	0.000791	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.69e-05	0.00079	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.69e-05	0.000789	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.65e-05	0.000778	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	2.55e-05	0.000748	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.54e-05	0.000746	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.53e-05	0.000744	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.53e-05	0.000743	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.52e-05	0.000741	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSR—amyotrophic lateral sclerosis	2.5e-05	0.000733	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.49e-05	0.000732	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.41e-05	0.000707	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.4e-05	0.000705	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.39e-05	0.000702	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.37e-05	0.000697	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.36e-05	0.000694	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.36e-05	0.000694	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.33e-05	0.000685	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.32e-05	0.000683	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.31e-05	0.000679	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.29e-05	0.000673	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.29e-05	0.000673	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.29e-05	0.000672	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.14e-05	0.00063	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.14e-05	0.00063	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.09e-05	0.000615	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.09e-05	0.000615	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	2.09e-05	0.000613	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.09e-05	0.000613	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.07e-05	0.000608	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.06e-05	0.000606	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.05e-05	0.000602	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.05e-05	0.000601	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.04e-05	0.000599	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.04e-05	0.000598	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.03e-05	0.000597	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.01e-05	0.00059	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.97e-05	0.00058	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.95e-05	0.000572	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.93e-05	0.000566	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.92e-05	0.000565	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.92e-05	0.000564	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.88e-05	0.000552	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.83e-05	0.000538	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.82e-05	0.000535	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.77e-05	0.00052	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.75e-05	0.000515	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.75e-05	0.000513	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.71e-05	0.000503	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.71e-05	0.000501	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.68e-05	0.000493	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.67e-05	0.000489	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.66e-05	0.000488	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.66e-05	0.000486	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.63e-05	0.00048	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.63e-05	0.000477	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.62e-05	0.000477	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.58e-05	0.000464	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.54e-05	0.000453	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.52e-05	0.000447	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.51e-05	0.000444	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.51e-05	0.000443	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.5e-05	0.000441	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.48e-05	0.000436	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.45e-05	0.000427	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.45e-05	0.000426	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.44e-05	0.000424	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.41e-05	0.000413	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.4e-05	0.000412	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.38e-05	0.000405	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.37e-05	0.000404	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.37e-05	0.000401	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.32e-05	0.000387	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.31e-05	0.000386	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.29e-05	0.00038	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.26e-05	0.000369	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.25e-05	0.000369	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.25e-05	0.000368	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.24e-05	0.000364	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.23e-05	0.000362	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.23e-05	0.000362	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.17e-05	0.000343	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.16e-05	0.00034	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.12e-05	0.00033	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.12e-05	0.00033	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.1e-05	0.000324	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.07e-05	0.000316	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.07e-05	0.000315	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.05e-05	0.00031	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.03e-05	0.000304	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.03e-05	0.000303	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000297	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000297	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000296	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.92e-06	0.000291	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.88e-06	0.00029	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.6e-06	0.000282	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	9.51e-06	0.000279	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.93e-06	0.000262	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.9e-06	0.000262	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.77e-06	0.000258	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	8.5e-06	0.00025	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.5e-06	0.00025	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	8.33e-06	0.000245	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.32e-06	0.000244	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.29e-06	0.000244	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.29e-06	0.000244	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.16e-06	0.00024	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.93e-06	0.000233	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.81e-06	0.00023	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.81e-06	0.000229	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.7e-06	0.000226	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.62e-06	0.000224	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.18e-06	0.000211	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.87e-06	0.000202	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.85e-06	0.000201	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.74e-06	0.000198	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.62e-06	0.000194	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	6.42e-06	0.000189	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	6.27e-06	0.000184	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.1e-06	0.000179	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.08e-06	0.000179	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.91e-06	0.000174	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.82e-06	0.000171	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.77e-06	0.000169	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.71e-06	0.000168	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.29e-06	0.000155	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.27e-06	0.000155	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.19e-06	0.000152	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.18e-06	0.000152	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.11e-06	0.00015	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	5.01e-06	0.000147	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5e-06	0.000147	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.98e-06	0.000146	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.9e-06	0.000144	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.7e-06	0.000138	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.49e-06	0.000132	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.47e-06	0.000131	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.4e-06	0.000129	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.4e-06	0.000129	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.3e-06	0.000126	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.05e-06	0.000119	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.91e-06	0.000115	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.86e-06	0.000113	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.43e-06	0.000101	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.39e-06	9.96e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.38e-06	9.93e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.33e-06	9.78e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.65e-06	7.78e-05	CbGpPWpGaD
